A Randomized Phase II/III Study of Paclitaxel/Carboplatin/Metformin (NSC# 91485) versus Paclitaxel/Carboplatin/Placebo as Initial Therapy for Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial Cancer NCT #02065687
This randomized phase II/III trial studies how well paclitaxel, carboplatin, and metformin
hydrochloride works and compares it to paclitaxel, carboplatin, and placebo in treating
patients with endometrial cancer that is stage III, IV, or has come back. Drugs used in
chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth
of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping
them from spreading. Metformin hydrochloride may help paclitaxel and carboplatin work better
by making cancer cells more sensitive to the drugs. It is not yet known whether paclitaxel
and carboplatin is more effective with or without metformin hydrochloride in treating
View more details from ClinicalTrials.gov.
For more information about a clinical trial, clinical trial eligibility, or informed consent, contact our research nurses by phone or email:
Please Note: Any eligibility criteria noted are subject to change. Our research nurses can provide you with the most current eligibility and exclusion criteria. Any study involvement to be undertaken must ultimately be determined on an individual basis.